Abstract
Relevance. Primary chronic osteomyelitis (PCO) is a rare condition that poses diagnostic challenges, primarily affecting children between the ages of 5 and 17. It can occur in various bones, including the mandible in the maxillofacial region. The complexity of distinguishing PCO from infections, tumors, metabolic disorders, and other inflammatory conditions has led to misdiagnoses, resulting in inappropriate treatment strategies and recurrent episodes. Currently, there is no standardized treatment protocol for PCO, with most therapies starting with non-steroidal anti-inflammatory drugs (NSAIDs) to manage symptoms. The purpose of this case report is to find a new treatment approach by using monoclonal antibodies such as Denosumab in the treatment protocol. Monoclonal antibodies like Denosumab have shown promising results by targeting the RANKL-RANK interaction, inhibiting osteoclast activity, and reducing inflammatory bone resorption. Materials and Methods: In the Department of Maxillofacial Surgery of the Russian Children’s Clinical Hospital - a branch of the Federal State Autonomous Educational Institution of Higher Education Russian National Research Medical University named after. N.I. Pirogov of the Ministry of Health of the Russian Federation of Moscow from 2015 to 2023, 45 children underwent inpatient treatment for primary chronic osteomyelitis (PCO). Of these, 17 children received combination therapy, which included decortication with removal of all granulomatous tissue and administration of the drug Denosumab, and that is after receiving negative culture results which conforms the diagnose of PCO. From these 17 patients, a 9-year-old girl with a persistently relapsing course was selected for this article. Results: The treatment methods employed in this clinical case successfully increased the density of the affected area. However, if small cystic components were retained and the sanitation of the granulated tissues was incomplete, a relapse occurred, necessitating repeated surgical treatment. Conclusion: By using this approach, we found that the intervals between collapses have been prolonged; leaving no doubt that the addition of Denosumab to the treatment protocol has played a significant role in achieving this optimal result by maintaining remission stability, even after the symptoms disappeared.

This publication has 16 references indexed in Scilit: